Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Medical CoTSE:7775 +0.24%64 Return-on-Tangible-Asset is 2.92% as of Mar. 2026, which is 64% below its 10-year median of 8.03. GuruFocus rates TSE:7775 with a GF Score™ of 64/100 and a GF Value™ of 円556.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Daiken Medical Co ranks better than 77.08% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Daiken Medical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was 円327 Mil. Daiken Medical Co's average total tangible assets for the quarter that ended in Mar. 2026 was 円11,222 Mil. Therefore, Daiken Medical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 2.92%.
The historical rank and industry rank for Daiken Medical Co's Return-on-Tangible-Asset or its related term are showing as below:
TSE:7775'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.22 Med: 8.03 Max: 11.86
Current: 8.33
During the past 13 years, Daiken Medical Co's highest Return-on-Tangible-Asset was 11.86%. The lowest was 6.22%. And the median was 8.03%.
TSE:7775's Return-on-Tangible-Asset is ranked better than 77.08% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.74
vs TSE:7775: 8.33
Daiken Medical Co (TSE:7775) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Daiken Medical Co Return-on-Tangible-Asset Related Terms
Daiken Medical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Daiken Medical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7775 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Daiken Medical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Medical Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Daiken Medical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Daiken Medical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.92% mean?
Daiken Medical Co (TSE:7775) has a Return-on-Tangible-Asset of 2.92% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiken Medical Co and its competitors. This is 64% below median its historical median of 8.03. Over the past decade, Daiken Medical Co's Return-on-Tangible-Asset has ranged from 6.22 to 11.86. According to the industry distribution chart, Daiken Medical Co ranks #196 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Daiken Medical Co's Return-on-Tangible-Asset too high?
Daiken Medical Co's current Return-on-Tangible-Asset of 2.92% is 64% below median its 10-year median of 8.03. Over the past 10 years, this metric has ranged from a low of 6.22 to a high of 11.86. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. Daiken Medical Co's value of 2.92% is 294.6% above this industry median. Based on the distribution chart, Daiken Medical Co ranks #196 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Daiken Medical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiken Medical Co's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Daiken Medical Co ranks #196 out of 855 companies for Return-on-Tangible-Asset. This places Daiken Medical Co in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.74. Daiken Medical Co's value of 2.92% is 294.6% above this benchmark. Historically, Daiken Medical Co's own Return-on-Tangible-Asset has ranged from 6.22 to 11.86 over the past decade. While the company's 10-year median is 8.03 vs. the industry median of 0.74, Daiken Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Medical Co's current Return-on-Tangible-Asset of 2.92% is 294.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiken Medical Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Medical Co's current Return-on-Tangible-Asset is 2.92%, which is 64% below median its own 10-year median of 8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Daiken Medical Co (TSE:7775) is currently considered Modestly Undervalued. The stock's GF Value™ is 円556.99, compared to a current price of 円425.00 — trading 23.7% below its estimated fair value. The current Return-on-Tangible-Asset is 2.92%, which is 64% below median its 10-year median of 8.03 and 294.6% above the Medical Devices & Instruments industry median of 0.74. Daiken Medical Co's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Daiken Medical Co (TSE:7775), the current Return-on-Tangible-Asset is 2.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiken Medical Co (TSE:7775) Overvalued in 2026?
Based on GuruFocus' analysis, Daiken Medical Co stock appears to be undervalued.
The current stock price of 円425.00 is trading 23.7% below its estimated GF Value™ of 円556.99.
GuruFocus considers Daiken Medical Co to be Modestly Undervalued.
Key valuation signals for TSE:7775:
Return-on-Tangible-Asset: 2.92% (64% below median its 10-year median of 8.03)
GF Value™: 円556.99 vs. price of 円425.00 (23.7% below fair value)
Industry Position: 294.6% above the Medical Devices & Instruments median (#196 of 855)
No single metric tells the full story. See the TSE:7775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiken Medical Co Ltd manufactures and sells medical equipment. The product line includes - Coopdech syrinjector, Coopdech Syrinjector PCA device, Coopdech Balloonjector, Coopdech Endobronchial blocker tube, Coopdech double-lumen endobronchial tube, Fit fix suction container system, Wet disinfectant mat, and others.
64GF Score
Get the complete analysis for TSE:7775
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7775 has been successfully added to your 
